Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06279793
Other study ID # MODIFYCSX
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 15, 2024
Est. completion date December 1, 2025

Study information

Verified date September 2023
Source GCP-Service International West GmbH
Contact Christian Stoppe, Prof. Dr.
Phone +49 931 201-30001
Email cstoppe@gcp-service.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposing study is a randomized, double-blind, controlled trial of about 120 patients in 10 centers in Germany. This trial will be started in Germany and recruited mainly at powerful German heart centers only. In this prospective randomized controlled blinded multicenter trial, a total of 120 high-risk cardiac surgery patients will receive either standard of care + OMEGAVEN at 0.20 g/kg ideal body weight (IBW) versus placebo + standard of care.


Description:

The proposed hypothesize is that the therapeutic strategy tested in this randomized trial will decrease the occurrence of postoperative atrial fibrillation, which ultimately lead to faster time to discharge alive. This turn significantly improves the patients' mid and long-term outcomes and dramatically reduces associated healthcare related costs. Duration of intervention: until discharge from ICU, death or postoperative day 7 on ICU, whichever comes first. Treatment Group: Patients will receive Omegaven® in dose 0.20 g/kg/d. Control Group: Patients will receive 0,9% NaCl in dose 0.20 g/kg/d (placebo). Follow-up per patient: at day 30, month 3, 6, and 12 months. Primary endpoint (phase II study): The primary endpoint for this phase II clinical trial will be the presence of new onset atrial fibrillation after cardiac surgery (AFACS) until day 7 after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent prior to study participation 2. Adult patients (= 18 years) 3. Patients scheduled to undergo elective cardiac surgery with the use of cardiopulmonary bypass (CPB), who are defined as high risk based on having (i) combined valve/coronary artery bypass graft (CABG) or multiple valve surgeries, or combined cardiac/aortic surgical procedures and (ii) one of the following additional risk factors: 1. a high perioperative risk profile, defined as predicted operative mortality of = 8% (European System for Cardiac Operative Risk Evaluation, EuroSCORE II). 2. Age >70 3. Clinical Frailty Score 4 or more 4. Urgent surgery (defined as to be performed within 24-48 hours after admission) 5. Left ventricular ejection fraction <35% Exclusion Criteria: 1. Known hypersensitivity to fish oil (FO)/ fish products or egg protein 2. Pregnancy or lactation period 3. Previous history of atrial fibrillation, atrial flutter and/or atrial tachyarrhythmia 4. Inability or unwillingness of individual to give written informed consent 5. Not expected to survive an additional 48 hours from screening evaluation 6. Lack of commitment to full, aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated "Do not Resuscitate" (DNR) acceptable) 7. Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma 8. Patients receiving and extracorporeal mechanical assist device (e.g. extracorporal life support systems [ECLS], or intra-aortic ballon pump [IABP]) or for advanced heart failure therapies (e.g. platelet aggregation inhibitors [TAH], ventricular assist devices [VAD]) 9. Enrolment in anyinterventional trial within the last 30 days 10. Already receiving FO-containing medical nutrition products 11. Severe malnutrition (as defined by the BMI<18.5) 12. Severe liver dysfunction defined by Child Pugh Class C. 13. Severe chronic kidney dysfunction defined by the National Kidney Foundation (NKF) stage 4 and 5 by using the glomerular filtration rate (GFR < 30ml/min)1 14. Known severe coagulation disorder

Study Design


Intervention

Drug:
Long-chain n-3 fatty acids
Omegaven is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids. Omegaven is manufactured by Fresenius-Kabi, Germany and is available in 100 ml bottles for study purpose. Each 100 ml of Omegaven contains 10 grams of fish oil (10 ml/gm or 0.1grams/ml). Timeframe: Day -1: The treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion. Intraoperative Day: No dose Post OP (Day 0): study drug 0.20 grams/kg IBW/day Post OP ( Day 1 to max Day 7): study drug 0.20 grams/kg IBW/day
Intravenous 0.9% Sodium Chloride
Intravenous 0.9% Sodium Chloride

Locations

Country Name City State
Germany RWTH Aachen University Aachen
Germany Charité Universitätsmedizin Berlin Berlin
Germany University of Bonn Bonn
Germany Universität Göttingen Göttingen
Germany University Medical Center Schleswig-Holstein Kiel
Germany University of Muenster Münster

Sponsors (3)

Lead Sponsor Collaborator
GCP-Service International West GmbH Charite University, Berlin, Germany, Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Optional-Ultrasound measurement nested sub-study of skeletal muscle mass screening, ICU discharge, hospital discharge
Other Optional-Functional Status Score for Intensive Care Unit Functional Status Score screening, ICU discharge
Other Optional-Short Physical Performance Battery test nested sub-study screening, ICU discharge, hospital discharge
Other Optional-Hand grip dynamometer nested sub-study screening, ICU discharge, hospital discharge
Other Optional-Hand held dynamometer nested sub-study screening, ICU discharge, hospital discharge
Other Optional-Manual Muscle Testing nested sub-study screening, ICU discharge, hospital discharge
Other Optional-Left ventricular ejection function if available hospital discharg, 30 days, 3, 6 and 12 months
Other Optional-Markers of inflammation e.g. procalcitonin [PCT] interleukine-6 [IL-6], white blood cells [WBC] day 0-7
Other Optional-Hemodynamics Adequate hemodynamic support, as defined by stable Cardiac Index (CI), cardiac output (CO), Cardiac Power Index, mean arterial pressure (MAP), central vein pressure (CVP), pulmonary artery diastolic pressure day 0-7
Other Sub-study a serial blood samples and tissue samples( if available from the routine surgical procedure only). day -1, day 0-7, hopital discharge
Primary Atrial fibrillation The primary objective is to demonstrate superiority of Omegaven® compared to placebo in the prevention of atrial fibrilation Until 7 days after surgery
Secondary Weaning from cardiopulmonary bypass (CPB) Number of attempts to wean from CPB during surgery During surgery
Secondary Time to discharge alive time to be alive and discharge from Intensive Care Unit (ICU) at ICU discharge
Secondary Persistent Organ Dysfunction + Death requiring supportive technologies during the convalescent phase of critical illness day 30
Secondary Days alive and out of hospital time to be alive and discharge from Hospital 30 days, 3, 6 and 12 months
Secondary Hospital length of stay Number of days alive in the ICU/Hosp at hospital discharge
Secondary ICU length of stay Number of days alive in the ICU/Hosp at ICU discharge
Secondary Simplified Acute Physiology Score Estimates the probability of mortality for ICU patients on admission day 0-7
Secondary Therapeutic Intervention Scoring System a method for measuring workload and calculating costs in the ICU day 0-7
Secondary ICU and Hospital Readmission rates readmission to ICU and hospital 30 days, 3, 6 and 12 months
Secondary Delta Sequential Organ Failure Assessment Score (SOFA) Score a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category. day 0-7
Secondary Mechanical ventilation Duration of mechanical ventilation day -1-7
Secondary Stroke Incidence of stroke day 0-7
Secondary Acute Kidney Injury Kidney Disease: Improving Global Outcomes [KDIGO] stages 1-3 day 0-7
Secondary Infections rate Number of infections screening, day -1-7
Secondary Clinical frailty scale a 9-point scale that quantifies frailty based on function in individual patients screening, day 30, 3 months
Secondary Development of delirium assessed by the CAM ICU score day 0-7, ICU discharge
Secondary Survival status overall survival hospital discharge, 30 days, 3, 6 and 12 months
Secondary Physical activity assessment Katz activities of daily living (ADL) and Lawton's Instrumental ADL (IADL) screening, 30 days, 3, and 6 months
Secondary Quality of Life (SF-36) to measure thew quality of life screening, 30 days, 3, 6, and 12 months
Secondary Adverse Events possibly related to the investigational product from day 0 to 12 months
Secondary Postoperative bleeding bleeding after surgery day 0-7
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3